Newsfeeds Archive - Spark Newswire

2 minute read

Industry Groups Back GSK’s Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer

June 20, 2:03 PM

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

GSK

1 minute read

News

Innate Pharma And Sanofi’s Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress

By Benzinga Newsdesk

June 17, 2:20 AM

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by

IPHA

2 minute read

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients

By Vandana Singh

June 4, 3:18 PM

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

SNY

2 minute read

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

By Vandana Singh

June 3, 9:53 AM

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK

2 minute read

FDA Extends Review Deadline For Regeneron/Sanofi’s Dupixent For ‘Smoker’s Lungs’ Disease

By Vandana Singh

May 31, 9:23 AM

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from pivotal trials. European Medicines Agency also supports Dupixent for COPD.

REGN

3 minute read

VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3

By Chris Katje

May 29, 6:23 PM

For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conference that combines elements of business, pop culture

COIN

2 minute read

Wall Street’s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

By Avi Kapoor

May 28, 8:56 AM

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors…

BMY

2 minute read

Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit

By Vandana Singh

May 24, 1:45 PM

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.

GSK

1 minute read

First Advanced Oral Treatment For Asthma – Sanofi’s Investigational Drug Shows Potential

By Vandana Singh

May 22, 1:59 PM

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

GSK

2 minute read

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M

By Vandana Singh

May 22, 1:25 PM

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous $834 million judgment

BMY